[Research progress in neoadjuvant therapy for epithelial ovarian cancer]

Zhonghua Fu Chan Ke Za Zhi. 2025 Jan 25;60(1):71-78. doi: 10.3760/cma.j.cn112141-20240930-00532.
[Article in Chinese]

Abstract

卵巢上皮性癌（卵巢癌）在妇科恶性肿瘤中的病死率最高，预后最差，对于不能行满意肿瘤细胞减灭术的晚期卵巢癌患者，新辅助治疗成为首选。单纯新辅助化疗的疗效有限且可能诱导耐药，不利于患者预后，而靶向治疗、聚二磷酸腺苷核糖聚合酶抑制剂（PARPi）治疗、免疫治疗和腹腔热灌注化疗（HIPEC）的疗效显著且毒副反应可接受，有望成为颇具前景的替代方案。本文对国内外应用靶向治疗、PARPi治疗、免疫治疗和HIPEC作为晚期卵巢癌新辅助治疗方案的研究进行了全面综述，为改进卵巢癌新辅助治疗的用药方案提供了理论依据和研究思路。.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Ovarian Epithelial* / drug therapy
  • Carcinoma, Ovarian Epithelial* / therapy
  • Chemotherapy, Adjuvant / methods
  • Female
  • Humans
  • Immunotherapy* / methods
  • Molecular Targeted Therapy
  • Neoadjuvant Therapy* / methods
  • Ovarian Neoplasms* / pathology
  • Ovarian Neoplasms* / therapy
  • Poly(ADP-ribose) Polymerase Inhibitors* / administration & dosage
  • Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use
  • Prognosis

Substances

  • Poly(ADP-ribose) Polymerase Inhibitors
  • Antineoplastic Agents